Sherene Loi

Sherene Loi: Neoadjuvant Atezolizumab in Early TNBC

Sherene Loi, Medical Oncologist, Lab Head of Breast Oncology Clinical Trials at Peter MacCallum Cancer Centre, posted on X:

“Final results of IMpassion031.
Neoadjuvant Atezolizumab in early TNBC Final EFS HR~ Gepardouze. ctDNA neg by Signatera not sensitive enough to say patients are cured but small % who were pos did poorly. Hopefully next gen ctDNA assays will be better.”

Read Further.

More posts featuring Breast Cancer.